No price history available.
Key financial summary
Financials in ILA| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ILAm | 0 | 0 | 0 | 0 | 0 | 0 | N/A | N/A |
| Operating profit | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ILAm | -22 | -90 | -39 | -29 | -28 | -24 | N/A | N/A |
| EPS reported | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ILAm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ILA | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in ILA| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Bonus BioGroup Ltd. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions through tissue engineering and cell-based therapies. Their flagship products include BonoFill, which is developed for regenerating bone tissue in maxillofacial and orthopedic applications, and MesenCure, aimed at treating COVID-19 patients suffering from pneumonia and acute respiratory distress syndrome (ARDS), as well as other life-threatening acute inflammatory illnesses. The company's innovation pipeline encompasses bone augmentation treatments for individuals with osteoporosis, cutting-edge nano-materials for drug delivery systems, and advancements in vascularized bone and soft tissue grafts. Originally known as Oceana Advanced Industries Ltd., the company was founded in 1981 and operates from Haifa, Israel.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Bonus BioGroup Ltd. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions through tissue engineering and cell-based therapies. Their flagship products include BonoFill, which is developed for regenerating bone tissue in maxillofacial and orthopedic applications, and MesenCure, aimed at treating COVID-19 patients suffering from pneumonia and acute respiratory distress syndrome (ARDS), as well as other life-threatening acute inflammatory illnesses. The company's innovation pipeline encompasses bone augmentation treatments for individuals with osteoporosis, cutting-edge nano-materials for drug delivery systems, and advancements in vascularized bone and soft tissue grafts. Originally known as Oceana Advanced Industries Ltd., the company was founded in 1981 and operates from Haifa, Israel.